On June 15, 2020, the Food and Drug Administration (FDA) determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19, and thus revoked the previous Emergency Use Authorization (EUA). Based on emerging scientific data, concerns due to serious cardiac adverse events, and other potential serious side effects, the agency decided the benefits of both agents no longer outweigh the potential risks for the authorized use. These agents could still be used by physicians as off label treatment if deemed appropriate. 
On June 20, 2020, the National Institutes of Health (NIH) stopped a clinical trial (the Outcomes Related to COIVD-19 treated with hydroxychloroquine among inpatients with symptomatic disease study [ORCHID] study) to assess the efficacy and safety of hydroxychloroquine to treat COVID-19 patients. This decision comes after a fourth interim analysis showing the drug was very likely to not be beneficial to hospitalized COVID-19 patients while also showing no harms. More than 470 patients were enrolled at the time of the study’s closure. 
On July 4, 2020, the World Health Organization (WHO) accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The recommendation was made based on the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results and from a review of the evidence from all trials presented at the July 1-2 WHO Summit on COVID-19 research and innovation. The interim results for both treatments show little to no reduction in mortality in hospitalized COVID-19 patients compared to standard of care. Although there was no solid evidence of increased mortality, there was also a safety concern with these agents.